Your selection

Research / 17.06.2022
Maike Sander named to lead the Max Delbrück Center

Prof. Dr. Maike Sander (Foto: Peter Himsel/MDC)
Prof. Dr. Maike Sander (Foto: Peter Himsel/MDC)

Maike Sander has been selected to direct the Max Delbrück Center for Molecular Medicine (MDC). The Supervisory Board appointed the diabetes researcher and professor of pediatrics and cellular and molecular medicine as the Scientific Director and Chair of the Board on June 16, 2022.

On November 1, 2022, Prof. Maike Sander will take the reins as Scientific Director and Chair of the Board of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). The Supervisory Board of the MDC formally appointed her to the post on Thursday, June 16, 2022. The MDC, which is celebrating its 30th anniversary this year, is one of five Health Centers in the Helmholtz Association of German Research Centers. The internationally renowned researcher and experienced science manager Maike Sander will be succeeding Prof. Thomas Sommer, who has directed the MDC on an interim basis since 2019. That will make Sander the first woman to head one of the Helmholtz Health Centers.

“The MDC has distinguished itself as an internationally renowned center for highly innovative biomedical research,” says Maike Sander. “Work at the MDC lays the foundation for better medicine of the future. The MDC provides on outstanding environment for research and attracts talent from around the globe. I had the opportunity to experience this first-hand as a visiting professor at the MDC. As Scientific Director, my goal will be to further strengthen the MDC’s role as a leading biomedical research center and to deepen partnerships with other institutions in Berlin and beyond, so that our discoveries can be rapidly turned into medical innovations.” Sander emphasizes that “medical innovation needs strong basic science, clinical science and industry partners – components that are all part of the vibrant Berlin biomedical ecosystem,” she points out. “The Berlin region is developing into a flourishing biotech pharma hub and I see the MDC as a principal driver of innovation in this landscape. I very much look forward to working with all stakeholders across Berlin.”

Novel therapeutic approaches for diabetes

Maike Sander’s research focuses on identifying novel therapeutic approaches for diabetes. To this end, Sander studies the molecular mechanisms that underlie the formation and function of the different cell types in the pancreas, in particular the insulin-producing beta cells. Her goal is to identify strategies for replacing beta cells in diabetes using beta cells derived from human pluripotent stem cells. 

Since 2012, Sander has served as the Director of the Pediatric Diabetes Research Center at the University of California, San Diego (UC San Diego), where she is also a Professor in the Departments of Pediatrics and Cellular & Molecular Medicine. In Berlin, Maike Sander will be appointed as Professor at the Charité – Universitätsmedizin.

German Research Minister: An outstanding scientist with international experience

“Maike Sander is an outstanding scientist with a track record of innovation in biomedical research,” says Bettina Stark-Watzinger, Germany’s Federal Minister of Education and Research. “I am delighted we have been able to bring her back to Germany after many years in the United States and to win her as the new Scientific Director of the Max Delbrück Center. It demonstrates the attractiveness of Berlin as a hub for biomedical research. As a scientist and administrator, Prof. Sander is the perfect match for the MDC with its mission to improve human health through transformative biomedical research. Also, having a female leader is an important signal. Prof. Sander’s appointment represents a significant gain for German research.”

Berlin’s Senator for Higher Education and Research, Health, Long-Term Care and Gender Equality, Ulrike Gote, says: “In Prof. Maike Sander, the Max Delbrück Center has gained an internationally renowned scientist as its new Scientific Director. I warmly welcome her to the science and healthcare metropolis Berlin. Prof. Sander’s expertise and experience provide the ideal background for future development of the MDC and for increasing the international visibility of the vibrant life sciences community at the MDC and in Berlin. As the senator in charge of higher education, research, and gender equality, I am delighted to see a woman at the helm of a Helmholtz Health Center.”

Wiestler: The Helmholtz Association stands to benefit tremendously

“I got to know Maike Sander as an expert in diabetes and stem cells when she was a visiting professor at the MDC,” says Otmar D. Wiestler, President of the Helmholtz Association. “With her high scientific standing and international experience, she is the ideal person to determine the future direction of the MDC as Scientific Director and Chair of the Board. With Prof. Sander we are gaining an excellent scientist whose expertise will be of tremendous benefit to the Helmholtz Association. A critical focus area is the development of precision medicine approaches. The MDC is at the forefront of advancing research in this important area. I look forward to working with Prof. Sander and to a vivid exchange of ideas.”

About Maike Sander

Maike Sander, a native of Göttingen, is 54 years old. After graduating with a medical degree from the University of Heidelberg Medical School in 1994, she conducted research at the University of California, San Francisco. Before moving to UC San Diego in 2008, she held faculty positions at Hamburg Medical School and the University of California, Irvine. An expert on insulin-producing pancreatic beta cells, she has nearly 30 years of experience in medicine and diabetes research.  

Sander is an elected member of the German National Academy of Sciences Leopoldina, the Association of American Physicians, and the American Society of Clinical Investigation. In addition, she is a member of two NIH consortia: The Human Islet Research Network and the NIH Impact of Genomic Variation on Function Consortium, which seeks to define basic mechanisms of gene regulation. 
 
She is a recipient of the Grodsky Award of the Juvenile Diabetes Research Foundation, the 2022 Albert Renold Prize of the European Association for the Study of Diabetes, and the Alexander von Humboldt Foundation Research Award. Since 2019, Sander has been an Einstein Visiting Fellow at the Berlin Institute of Health at Charité (BIH).

Source: Press Release MDC
Maike Sander named to lead the Max Delbrück Center

Overview News

News Buch Berlin

Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX), has announced that the U.S. National Institute of Allergy and Infectious Diseases (...

more ...

Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)

Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.

more ...

Unchartered territory in the human genome

An international consortium brings together 7,200 segments of the human genome that are virtually unexplored and presents a roadmap for integrating them into genome databases in “Nature Biotechnology”...

more ...

Events Buch Berlin

23.08.2022, 14:30
Geführte Wanderungen durch die denkmalgeschützten Bereiche in Buch

Manfred Pinkwart lädt Sie ein zur Führung durch den Schlosspark Buch

more ...

27.08.2022, 14:00
Gauklerfest auf der Moorwiese

Der Archäologie- und Abenteuerspielplatz lädt wieder zum Gauklerfest ein

more ...

31.08.2022, 09:00
From Target to Market - The GLA Biotech & Pharma Summer School

The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea until to market.

more ...

This website is supported by: